Navigation Links
Sunesis Pharmaceuticals to Present Data on Two Product Candidates at the 49th Annual Meeting of the American Society of Hematology
Date:11/29/2007

Management and Third-Party Investigators to Conduct Conference Call on December 10, 2007 to Discuss SNS-595 Clinical Trial Results and SNS-032

Non-clinical Data

SOUTH SAN FRANCISCO, Calif., Nov. 29 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS), a clinical-stage biopharmaceutical company developing novel anticancer therapeutics, today announced that it will present data on the company's two lead product candidates, SNS-595 and SNS-032, at the upcoming 49th Annual Meeting of the American Society of Hematology (ASH). This year's conference will be held December 8-11, 2007 at the Georgia World Congress Center in Atlanta, Georgia. On December 10, 2007, Sunesis management will host a conference call for investors to discuss the data being presented.

Jeffrey Lancet, M.D., of the H. Lee Moffitt Cancer Center & Research Institute will present results from Sunesis' Phase 1 clinical trial of SNS-595, a replication-dependent DNA damaging agent, as part of the oral session "Acute Myeloid Leukemias: Therapy, excluding Transplantation-Novel Therapies." The presentation, titled "SNS-595 Demonstrates Clinical Responses in a Phase 1 Study in Acute Leukemia," (Abstract no. 442), will be conducted in Room A411-A412 at 2:15 p.m. Eastern Time on Monday, December 10, 2007.

In addition, the company will present non-clinical data on SNS-032, a cyclin-dependent kinase (CDK) inhibitor, during poster session "CLL: Salvage Therapies and New Agents." The poster, "Mechanism of Action of SNS-032, a Novel Cyclin Dependent Kinase Inhibitor, in Chronic Lymphocytic Leukemia: Comparison with Flavopiridol" (Abstract no. 3112) will be presented in Hall B4 of the Georgia World Congress Center on Monday December 10, 2007 from 10:30 a.m. to 7:00 p.m.

Conference Call Information

Sunesis management will host a conference call to discuss data being presented at the ASH meeting on Monday, December 10, 2007 at 4:00 p.m. Eastern Time/1:00 p.m. Pacific Time. Joining management on the call will be clinical investigators involved in the clinical trial of SNS-595and the non-clinical studies of SNS-032.

Individual and institutional investors can access the call via 877-723-9519 (U.S. and Canada) or 719-325-4841 (international). To access the live audio webcast, visit the "Investors and Media - Calendar of Events" section of the Sunesis website at http://www.sunesis.com. Please log on to Sunesis' website several minutes prior to the start of the presentation to ensure adequate time for any software download that may be necessary.

About Sunesis' Oncology Programs

Sunesis has built a rich portfolio of product candidates in oncology focused on novel pathways and targets, including inhibition of the cell-cycle and survival signaling. SNS-595, a replication-dependent DNA damaging agent, is currently in Phase 1 and Phase 1b clinical trials of patients with acute leukemia and a Phase 2 ovarian cancer clinical trial. SNS-032, Sunesis' CDK inhibitor, is being evaluated in a Phase 1 clinical trial in B-cell malignancies. SNS-314, an Aurora kinase inhibitor, is being studied in a Phase 1 dose-escalating clinical trial in patients with advanced solid tumors. In addition, Sunesis is developing novel small molecule inhibitors of Raf kinase and other oncology kinases in collaboration with Biogen Idec.

About Sunesis Pharmaceuticals

Sunesis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for oncology and other serious diseases. Sunesis has built a broad product candidate portfolio through internal discovery and in-licensing of novel cancer therapeutics. Sunesis is advancing its product candidates through in-house research and development efforts and strategic collaborations with leading pharmaceutical and biopharmaceutical companies. For additional information on Sunesis Pharmaceuticals, please visit http://www.sunesis.com.


'/>"/>
SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Sunesis Pharmaceuticals Commences Clinical Trials of SNS-595 and SNS-314
2. Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
7. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
8. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
9. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
10. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
11. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/10/2017)... 2017 Radiology has become the number one ... also spiraled to the number one ranking as a ... ever before as the most complete and reliable method ... lower back pain an MRI may confirm a suspected ... resulting in entirely different treatment protocols.  In these circumstances, ...
(Date:5/9/2017)... Ore. , May 9, 2017  Semler ... that provides technology solutions to improve the clinical ... financial results for the first quarter ended March ... our products enable our customers to identify when ... to intervene before events like heart attacks or ...
(Date:5/6/2017)... , May 5, 2017  Hill-Rom Holdings, Inc. (NYSE: ... approximately 100,000 square feet to its Welch Allyn campus. ... its commitment to bring more than 100 new jobs ... Welch Allyn has maintained a significant presence for more ... these new positions, a large portion of which will ...
Breaking Medicine Technology:
(Date:5/26/2017)... (PRWEB) , ... May 26, 2017 , ... ... met this week to review more than eighty-nine grant submissions all vying ... emerging young scientists in the Parkinson’s field.     , The American Parkinson Disease Association ...
(Date:5/26/2017)... ... May 26, 2017 , ... A new analysis of community health data reveals ... located in the Midwest. With the average cost of healthcare rising and the U.S. ... both the quality and affordability of where they live. An annual 2017 report looked ...
(Date:5/26/2017)... ... ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh in Abilene, Texas, ... being discussed by President Donald Trump and the rest of the world. Donald Trump ... peace talks in the continuous battle between Israel and Palestine. The world’s eyes are ...
(Date:5/26/2017)... ... 26, 2017 , ... “THE FLINTHILLS FAMILY-Our Journey to the Cross”: the personal journey of Bob ... is the creation of published authors, Bob and Margaret Massey. Bob Massey is small ... "panther quick and leather tough." His love for others is apparent in all of ...
(Date:5/24/2017)... ... 24, 2017 , ... Last month, representatives from Rendina Healthcare ... town officials to celebrate the grand opening of the 87,000 square foot medical ... of its ongoing relationship with RWJBarnabas Health, New Jersey’s largest health system. Two ...
Breaking Medicine News(10 mins):